Molecular Partners Ag (MOLN) Revenue (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Revenue of $17166.8 for Q1 2026, down 4.38% year-over-year from $17953.9 in Q1 2025, and up 130.19% quarter-over-quarter from -$56858.0 in Q4 2025.
Molecular Partners Ag (MOLN) Revenue (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Revenue for 7 consecutive years, with $17166.8 the latest figure, recorded in Q1 2026.
- In Q1 2026, Revenue fell 4.38% year-over-year to $17166.8; the TTM figure through Mar 2026 stood at -$3716.7 (down 100.0% YoY), while the FY2025 annual figure was $72.69, up 1173.61% from the prior year.
- Revenue advanced to $17166.8 in Q1 2026 per MOLN's latest filing, from -$56858.0 in the prior quarter.
- Across five years, Revenue topped out at $187.1 billion in Q1 2022 and bottomed at -$56858.0 in Q4 2025.
- Historically, Revenue has averaged $11.4 billion across 5 years, with a median of $20917.0 in 2025.
- Annual changes were most pronounced in 2022 — Revenue jumped 63614439.0% — and 2025, when it tumbled 903.2%.
- Molecular Partners Ag's Revenue stood at $155.5 million in 2022, then plunged by 94.9% to $7.9 million in 2023, then sank by 100.07% to -$5667.7 in 2024, then sank by 903.2% to -$56858.0 in 2025, then surged by 130.19% to $17166.8 in 2026.
- Business Quant data shows MOLN's Revenue at $17166.8 in Q1 2026, -$56858.0 in Q4 2025, and $15057.6 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.92 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.57 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 59.12 Bn | 53.98 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 31.75 Bn | 28.45 Bn | 992.69 Mn | 1.29 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.72 Bn | 668.28 Mn | 1.06 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 425.49 Mn |
| 9 | Royalty Pharma | 27.20 Bn | 26.36 Bn | - | 674.14 Mn |
| 10 | Molecular Partners Ag | 163.25 Mn | 163.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17,166.77 |
| Dec 31, 2025 | -56,858.03 |
| Sep 30, 2025 | 15,057.57 |
| Jun 30, 2025 | 20,917.04 |
| Mar 31, 2025 | 17,953.95 |
| Dec 31, 2024 | -5,667.66 |
| Sep 30, 2024 | 786.02 Mn |
| Jun 30, 2024 | 1.72 |
| Mar 31, 2024 | 3,136.88 |
| Dec 31, 2023 | 7.93 Mn |
| Sep 30, 2023 | 2,876.80 |
| Jun 30, 2023 | 461,552.85 |
| Mar 31, 2023 | 3.30 Bn |
| Dec 31, 2022 | 155.51 Mn |
| Sep 30, 2022 | 2.45 Bn |
| Jun 30, 2022 | 12.21 Mn |
| Mar 31, 2022 | 187.09 Bn |
| Dec 31, 2021 | -8.61 Bn |
| Sep 30, 2021 | 3,847.89 |
| Jun 30, 2021 | -1.07 Bn |